NEW YORK, June 5, 2012 /PRNewswire/ -- Deloitte, the largest professional services organization in the United States, has expanded its governance, regulatory and risk strategies (GRRS) practice with the addition of Michael Hercz as a director with Deloitte & Touche LLP to the life sciences sector. Hercz is based in Deloitte's Costa Mesa, Calif. office.
Hercz brings 15 years of industry experience in compliance and risk management, bolstered by a strong legal background in the healthcare and life sciences sector. Prior to joining Deloitte, he was vice president and chief compliance officer of Victory Pharma Inc., a specialty pharmaceutical company where he spearheaded the creation of the company's corporate compliance department.
Serving Deloitte's life sciences and health care industry group, Hercz further strengthens Deloitte's efforts to address the complex regulatory and compliance challenges facing organizations in the continually evolving life sciences and health care industry. He will assist clients to help them in achieving their strategic objectives including quality of care, shareholder value and profitability, while maintaining an effective balance with compliance and risk.
"We are delighted to welcome Michael to our team and look forward to sharing with our clients the wealth of legal, compliance, and risk management experience he brings in the life sciences arena," said Kevin McGovern, managing partner and U.S. leader, governance, regulatory and risk strategies practice, Deloitte & Touche LLP. "Michael's demonstrated track record in launching successful risk management and compliance departments for Amgen and Victory Pharma underscores his strong reputation in the industry."
"Deloitte has a solid reputation in the life sciences and health care industry and I look forward to being part of such a strong team," said Hercz. "The only constant in the industry's regulatory environment is change, which drives ever-increasing demand for compliance, regulation and risk mitigation services.
With Deloitte's reputation, breadth of knowledge and depth of services, we are strongly positioned to meet that demand. I look forward to sharing the knowledge I have gained over many years in this space and drawing upon the broad base of experience that is housed within Deloitte for the benefit of our clients."
Previously, Hercz served as executive director of the enterprise risk management department of the world's largest biotechnology company, Amgen Inc., where he designed and implemented both first and second generation corporate compliance programs. Additionally, he established and led the company's enterprise risk management function. Prior to working in the industry, Michael advised a wide range of healthcare and life sciences clients as an attorney at global law firm Akin, Gump, Strauss, Hauer & Feld LLP.
Hercz frequently presents at leading conferences on topics ranging from creating effective compliance programs to government enforcement trends. Most recently, he served as distinguished speaker for the Center for Business Intelligence (CBI's) 2011 and 2012 Forums on the Sunshine Act, State Laws and Aggregate Spend, and as a faculty member for the Orange County Regulatory Affairs Discussion Group and San Diego Regulatory Affairs Network.
A resident of San Clemente, Calif., Hercz holds a juris doctor from the University of Southern California and a bachelor's degree in psychology from the University of Pennsylvania.
About Deloitte's Governance, Regulatory & Risk Strategies (GRRS) practice
Deloitte's governance, regulatory & risk strategies practice professionals provide consultative services to organizations and their boards that are designed to create and protect value and enhance effective management of their strategic, regulatory, financial, operational, and compliance risks on a sustained basis. Deloitte helps develop sustainable governance, compliance, and risk management programs by helping organizations identify, remediate, monitor, exploit, and manage enterprise risks in addition to coordinating the utilization of people, process, and technology to improve effectiveness and help manage costs.
As used in this document, "Deloitte" means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.